Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …

JCH Yang, YL Wu, M Schuler, M Sebastian… - The lancet …, 2015 - thelancet.com
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
被引用次数：1774 相关文章

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …

JCH Yang, YL Wu, M Schuler, M Sebastian… - The Lancet …, 2015 - eprints.qut.edu.au
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
[PDF] qut.edu.au

[PDF][PDF] Effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma: outcomes of the two randomised Phase III trials LUX-Lung 3 …

JCH Yang, YL Wu, MS Martin Schuler, S Popat… - The Lancet … - eprints.qut.edu.au
Background Afatinib, an irreversible ErbB family blocker, improved progression-free survival
(PFS) versus pemetrexed/cisplatin (LUX-Lung-3 [LL3]) or gemcitabine/cisplatin (LUX-Lung-6 …
[PDF] tervisekassa.ee

[PDF][PDF] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data …

JCH Yang, YL Wu, MS Martin Schuler, S Popat… - Lancet …, 2015 - tervisekassa.ee
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …

JCH Yang, YL Wu, M Schuler… - The Lancet …, 2015 - pubmed.ncbi.nlm.nih.gov
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
[PDF] boehringerone.com

[PDF][PDF] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data …

JCH Yang, YL Wu, MS Martin Schuler, S Popat… - 2015 - boehringerone.com
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from …

JCH Yang, YL Wu, M Schuler… - The Lancet …, 2015 - researchoutput.ncku.edu.tw
Background: We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from …

JCH Yang, YL Wu, M Schuler, M Sebastian… - Lancet …, 2015 - ntur.lib.ntu.edu.tw
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …
[PDF] prensamedica.org

[PDF][PDF] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data …

JCH Yang, YL Wu, MS Martin Schuler, S Popat… - 2015 - prensamedica.org
Background We aimed to assess the effect of afatinib on overall survival of patients with
EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open …

[引用][C] Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data …

JCH Yang, YL Wu, MS Martin Schuler, S Popat… - The Lancet …, 2015 - cir.nii.ac.jp
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma
(LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 …